SCHEMBL4485984

SCHEMBL4485984

CCCc1nc(-c2ccccc2F)oc1C(=O)O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.46
MAPT P10636 3/20 0.46
THRB P10828 1/20 0.46
NPC1 O15118 1/20 0.45
RAB9A P51151 1/20 0.45
MEN1 O00255 3/20 0.44
KMT2A Q03164 3/20 0.44
ALDH1A1 P00352 1/20 0.44
CYP1A2 P05177 1/20 0.44
CYP3A4 P08684 1/20 0.44
CYP2C9 P11712 1/20 0.44
CYP2C19 P33261 1/20 0.44
TP53 P04637 1/20 0.44
POLB P06746 3/20 0.44
TSHR P16473 2/20 0.44
GAA P10253 1/20 0.44
C1R P00736 1/20 0.44
HTT P42858 2/20 0.42
PKM P14618 1/20 0.42
HPGD P15428 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4489532 0.86 SMN1; SMN2 (0.46) SMN1; SMN2MAPTTHRBNPC1RAB9A
SCHEMBL2790958 0.85 TSHR (0.47) MAPTTHRBKMT2AALDH1A1POLB
SCHEMBL4498797 0.85 TSHR (0.46) SMN1; SMN2MAPTTHRBNPC1RAB9A
SCHEMBL2792435 0.84 MAPT (0.44) SMN1; SMN2MAPTNPC1RAB9AMEN1
SCHEMBL2791277 0.84 SMN1; SMN2 (0.46) SMN1; SMN2MAPTALDH1A1CYP1A2CYP3A4
SCHEMBL27738187 0.83 NPC1 (0.41) SMN1; SMN2MAPTTHRBNPC1RAB9A
SCHEMBL2793763 0.82 KDM4E (0.56) SMN1; SMN2MAPTNPC1RAB9AKMT2A
SCHEMBL4493940 0.78 PPARG (0.47)
SCHEMBL4510686 0.77 KMT2A (0.52) SMN1; SMN2MAPTMEN1KMT2AALDH1A1
SCHEMBL27738189 0.77 NPC1 (0.43) SMN1; SMN2MAPTTHRBNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1917262-B1 PIPERIDINE AND PIPERAZINE DERIVATIVES AS P2X3 ANTAGONISTS HOFFMANN LA ROCHE (CH) 2011-12-14 EP disclosed
US-7491821-B2 2-(4-fluorophenyl)-4-propyl-oxazole-5-carboxylic acid {2-[4-(6-aminopyridin-2-yl)-piperazin-1-yl]-1-methyl-ethyl}amide; purinergic receptor antagonists, analgesics; urogenital, gastointestinal and respiratory system disorders ROCHE PALO ALTO LLC (US) 2009-02-17 US disclosed
EP-1917262-A1 PIPERIDINE AND PIPERAZINE DERIVATIVES AS P2X3 ANTAGONISTS F.HOFFMANN-LA ROCHE AG (CH) 2008-05-07 EP disclosed
WO-2007020194-A1 PIPERIDINE AND PIPERAZINE DERIVATIVES AS P2X3 ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2007-02-22 WO disclosed
US-20070037974-A1 Inhibitors of P2X3 ROCHE PALO ALTO LLC 2007-02-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070037974-A1 Inhibitors of P2X3 P2RX3, P2RX4, P2RX5 SMN1; SMN2 3624/4885MAPT 4669/4885THRB 389/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.